USFDA issues one observation for Cipla Bommasandra facility
Mumbai: Cipla has announced that the United States Food and Drugs Administration (USFDA) has concluded the inspection with one observation at the Company’s manufacturing facility in Bommasandra, Bengaluru.
The facility was inspected from 26th to 30th May 2025.
"We hereby notify that United States Food and Drugs Administration (‘USFDA’) has conducted a current Good Manufacturing Practices (‘cGMP’) inspection at the Company’s manufacturing facility in Bommasandra, Bengaluru from 26th to 30th May 2025," Cipla informed in a BSE filing.
"On conclusion of the inspection, the Company received 1 (one) observation in Form 483. The Company will work closely with the USFDA and remains committed to address the observation comprehensively within stipulated time," it added.
An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
Read also: Cipla arm to acquire 26% stake in AMPIN Energy C&I Eighteen
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in its home markets of India, South Africa, North America, and key regulated and emerging markets. It has strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS segments. It has 47 manufacturing sites around the world which produces 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to its 80+ markets.
Read also: New Role Alert: Amit Patel named Head - Consumer Marketing Excellence, Cipla India Rx
